Nivolumab for Squamous-Cell Cancer of Head and Neck.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Cancer organoids: A platform in basic and translational research.Genes & diseases · 2024
   Review
2. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.Cancer immunology research · 2019
   Article
3. Tumor organoids: A review of culture methods, applications in cancer research, precision medicine, and drug development.Tzu chi medical journal
   Review

Corrections and comments

• Commented on by
  Nivolumab for Squamous-Cell Cancer of Head and Neck.2017
• Comment on
  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as